Noventure S.L.U.
ES-MF-000000797 · Spain · BARCELONA
Noventure S.L.U. is registered in the European database on medical devices as a manufacturer, with 16 devices declared. It was not found in the U.S. FDA device establishment register.
What this manufacturer declares
| Class I | 12 |
|---|---|
| Class IIa | 3 |
| Class IIb | 1 |
Most frequent device types declared: Oleoabrax tube, Tasectan capsules, Tasectan sachets, UTA423, UTIPRO PLUS AF capsules.
Devices declared under this manufacturer
- CYS-CONTROL ULTRA
- Direxol
- Gelenterum 250 mg
- Novouro AF
- Oleoabrax 30 g muestra
- Tasectan 15 capsules
- Tasectan 20 sachets
- Tasectan 250 mg
- Tasectan 500 mg
- Tasectan AF
- URI-CRAN FORTE AF 15 capsules
- Utipro Plus AF
Showing 12 of 16 declared devices.
Catalogue references include 000000, 1291481, 1308499, 1308500, 1308533, 1308534.
European nomenclature codes declared: G99, G0499, G0402, M04040501, G0401.
United States market access
| FDA establishment register | Not found in the FDA register |
|---|---|
| Devices in EUDAMED | 16 |
| Country of registration | Spain |
⚠️ Not found is not the same as not sold — how this comparison can be wrong.
Device-level evidence
| Devices with a numeric GTIN | 14 |
|---|---|
| Found in the U.S. device database | 0 |
| Share | 0.0 % |
Canadian market access
| Health Canada licence listing | Not found in the Canadian register |
|---|
⚠️ Canada lists no Class I devices at all — what that excludes.
North American profile: Neither register. Noventure S.L.U. was not found in either the U.S. or the Canadian register.
Notified body certificates
| Certificate | Status | Expiry |
|---|---|---|
MDR00064-C | issued | 2029-11-14 |
MDR 00064-C | issued | 2029-11-14 |
MDR 00064-B | issued | 2029-11-14 |
MDR 00064-A | issued | 2029-11-14 |
CVD0023230226 | amended | 2028-12-21 |
CSQ0016230226 | amended | 2028-12-21 |